MedPath

Lung Therapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
First Posted Date
2020-01-18
Last Posted Date
2022-03-07
Lead Sponsor
Lung Therapeutics, Inc
Target Recruit Count
71
Registration Number
NCT04233814
Locations
🇬🇧

Celerion, Belfast, United Kingdom

A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions

Phase 2
Completed
Conditions
Pleural Effusion
Interventions
Drug: Placebo
First Posted Date
2019-11-12
Last Posted Date
2023-03-30
Lead Sponsor
Lung Therapeutics, Inc
Target Recruit Count
44
Registration Number
NCT04159831
Locations
🇺🇸

The University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

UC San Diego Health Jacobs Medical Center, La Jolla, California, United States

🇺🇸

University of California (UCLA), Los Angeles, California, United States

and more 30 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.